T. Harthaller

Immune response to 2-dose BNT162b2 vaccination and risk of SARS-CoV-2 breakthrough infection: The Shieldvacc-2 study

P. Willeit, L. Forer, F. Krammer, 2022, medRxiv.

Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak

P. Willeit, H. Winner, D. von Laer, 2022, Frontiers in Public Health.

Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria

P. Willeit, D. von Laer, Z. Bánki, 2022, Viruses.

High Prevalence of Undocumented SARS-CoV-2 Infections in the Pediatric Population of the Tyrolean District of Schwaz

D. von Laer, B. Falkensammer, W. Borena, 2022, Viruses.

Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial

K. Becker, P. Willeit, L. Forer, 2023, The Lancet. Microbe.

Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination

D. von Laer, R. Würzner, B. Falkensammer, 2023, Frontiers in immunology.